Allergan Lumigan Sales Aid Lacks Risk Info, Overstates Efficacy, FDA Says
Executive Summary
Allergan's dissemination of a sales aid for its glaucoma therapy Lumigan has prompted FDA's second letter to the company regarding product promotions in three months.
You may also be interested in...
Travatan and Lumigan Join Prostaglandin Class With March 16 Approval
Alcon's Travatan (travoprost) and Allergan's Lumigan (bimatoprost) are entering the prostaglandin analog class of glaucoma therapies following simultaneous approvals March 16.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials